Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to assess the therapeutic effects and the safety profile of
IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for
patients with advanced adenocarcinoma of the stomach, the esophagus or the gastroesophageal
junction compared to EOX alone.
Furthermore, sufficient binding of IMAB362 to the target cells is necessary for antitumoral
activity. Thus, two dose levels ensuring a serum level above the in vitro predicted clinical
efficacy threshold will be investigated.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc. Ganymed Pharmaceuticals AG